Athira Pharma (NASDAQ: ATHA) has announced that it has changed its name to LeonaBio (NASDAQ: LONA) effective January 12, 2026, to align with its acquisition of rights to develop and commercialize lasofoxifene, a late-stage clinical asset for the potential treatment of metastatic breast cancer.
In a statement, Mark Litton, PhD, president and CEO of LeonaBio, commented, “This marks an exciting and transformative period for our company and emphasizes our commitment to advancing a pipeline of innovative, late-stage assets both internally developed and strategically in-licensed with the goal of accelerating their path to market and maximizing their potential clinical and commercial impact.”
He added, “At LeonaBio, we are building a pipeline with the potential to change lives and create enduring value. Our new name truly reflects our commitment to leadership, resilience, and innovation—qualities that define our expanded mission to deliver transformative therapies for patients battling diseases that need better treatment options.”
